ARCOMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.05 SEK | +12.02% |
|
+11.54% | +64.15% |
| Jan. 29 | Arcoma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Arcoma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2024 * | 179M 16.36M | Sales 2025 * | 195M 17.82M | Capitalization | 154M 14.04M |
|---|---|---|---|---|---|
| Net income 2024 * | 9M 822K | Net income 2025 * | 12M 1.1M | EV / Sales 2024 * | 0.83 x |
| Net cash position 2024 * | 5M 457K | Net cash position 2025 * | 17M 1.55M | EV / Sales 2025 * | 0.7 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
12.9
x | Employees | 31 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +12.02% | ||
| 1 week | +11.54% | ||
| Current month | +9.66% | ||
| 1 month | +11.54% | ||
| 3 months | +61.11% | ||
| 6 months | +80.00% | ||
| Current year | +64.15% |
1 week
11.40
13.65
1 month
11.2513.65
Current year
7.6013.65
1 year
6.3013.65
3 years
6.3021.90
5 years
6.3026.30
10 years
3.5726.30
| Managers | Title | Age | Since |
|---|---|---|---|
Johan Dahlberg
DFI | Director of Finance/CFO | 40 | 21-12-31 |
| Chief Tech/Sci/R&D Officer | 53 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | - | |
| Director/Board Member | 53 | 10-02-28 | |
Lars Kvarnhem
CHM | Chairman | 52 | 16-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 13.05 | +12.02% | 329 806 |
| 24-04-24 | 11.65 | -2.10% | 49,419 |
| 24-04-23 | 11.9 | -0.83% | 10,220 |
| 24-04-22 | 12 | +3.45% | 28,564 |
| 24-04-19 | 11.6 | -0.85% | 8,235 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 09:03 am EDT
More quotes
Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +64.15% | 14.11M | |
| -8.27% | 14.29B | |
| -40.35% | 2.73B | |
| -16.64% | 2.34B | |
| -11.83% | 1.46B | |
| -.--% | 1.12B | |
| +42.70% | 525M | |
| +82.05% | 477M | |
| +8.76% | 227M | |
| +1.85% | 184M |
- Stock Market
- Equities
- ARCOMA Stock
